Puma Biotechnology launches Phase II ALISCA-Lung2 trial of alisertib plus paclitaxel in advanced small cell lung cancer

• Puma Biotechnology launched ALISCA-Lung2, a Phase II study of alisertib with paclitaxel in advanced small cell lung cancer.
• No trial results have been presented; readouts are expected in the future as enrollment progresses.
• Study targets about 50 previously treated patients, aiming to assess safety while gauging signals of anti-tumor activity.
• Biomarker work is planned to identify patient subgroups most likely to benefit, supporting future development decisions for alisertib.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917118471) on September 17, 2026, and is solely responsible for the information contained therein.